GRAND BLANC, Mich., Dec. 10, 2025 /PRNewswire/ — ModuleMD, ranked as one of America’s fastest-growing companies on the Inc. 5000 and top-rated EHR vendor on G2, announces SkinSight™ AI, a solution that brings automation, accuracy, and consistency to one of the most manual and variable workflows in allergy care: skin test measurement and documentation.
NEWPORT BEACH, Calif., Dec. 9, 2025 /PRNewswire/ — Medit, a global leader in 3D intraoral scanning and digital dentistry solutions, today announced the launch of AuraVue, a next-generation visualization and consultation platform that integrates Overjet’s AI technology to deliver real-time diagnostic insights and clearer patient communication.
TEL AVIV, Israel, Dec. 9, 2025 /PRNewswire/ — MedINT today announced the commercial launch of the first human-in-the-loop medical AI platform designed to return full control of evidence review and treatment decisions to clinicians managing complex patients. The system maintains clinician control at every step by delivering patient-specific evidence summaries that support clinical judgment without replacing it.
Resmed (NYSE: RMD)+
announced today that it received FDA clearance for its Smart Comfort personalized therapy offering.
Healthcare professionals can access the 1Bio AI-Acute toolbox via the company’s 1Bio platform.
Cancer isn’t just about broken genes—it’s about broken architecture. Imagine a city where roads suddenly vanish, cutting off neighborhoods from essential services. That’s what happens inside cells when the 3D structure of DNA collapses.
SURREY, BC, Dec. 4, 2025 /PRNewswire/ – mlHealth 360 today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance (K250694) for Scaida BrainCT-ICH, an AI-powered triage solution designed to address critical bottlenecks in acute care radiology.
Carlsmed (Nasdaq:CARL) announced today that it began the U.S. launch of its Aprevo technology platform for cervical fusion surgeries.
ST. PAUL, Minn., Dec. 3, 2025 /PRNewswire/ — Astrin Biosciences, a cancer intelligence company transforming how cancer is detected and treated through deep proteomics and AI, announced the launch of Certitude™, the first-of-its-kind, non-imaging, blood-based early cancer detection test. Results from the latest study will be presented at the upcoming San Antonio Breast Cancer Symposium (SABCS), taking place December 10–14, 2025.
Eko Health announced today that the Centers for Medicare & Medicaid Services (CMS) has finalized national payment for its Sensora platform.